Table 1.
Clinical trials with second-generation TRAs.
| TRAIL-R agonists | Setting | Cancer | Phase | Clinical trial identifier |
|---|---|---|---|---|
| SCB-313 | Monotherapy | Malignant Pleural Effusion | I | NCT04123886 |
| SCB-313 | Monotherapy | Malignant Ascites | I | NCT04051112 |
| SCB-313 | Monotherapy | Malignant Pleural Effusions | I | NCT03869697 |
| SCB-313 | Monotherapy | Peritoneal Malignancies | I | NCT03443674 |
| SCB-313 | Monotherapy | Peritoneal Carcinomatosis | I | NCT04047771 |
| MSCTRAIL | Monotherapy | Adenocarcinoma of Lung | I/II | NCT03298763 |
| ABBV-621 /APG880 | Combination therapy (Venetoclax, FOLFIRI, Bevacizumab) | Advanced Solid Tumors Hematologic Malignancies | I | NCT03082209 |
| ABBV-621 /APG881 | Combination therapy (Bortezomi, Dexamethasone) | Multiple Myeloma | I | NCT04570631 |
| INBRX-109 | Monotherapy | Conventional Chondrosarcoma | II | NCT04950075 |
| INBRX-109 | Combination therapy (Carboplatin, Cisplatin, Pemetrexed, 5-fluorouracil, Irinotecan, Temozolomide) | Solid Tumors, Malignant Pleural, Mesothelioma, Gastric Adenocarcinoma, Colorectal Adenocarcinoma, Sarcoma, Pancreatic Adenocarcinoma, Ewing Sarcoma, Chondrosarcoma | I | NCT03715933 |
| GEN1029 (HexaBody®-DR5/DR5) | Monotherapy | Colorectal Cancer, Non-small Cell Lung Cancer, Triple Negative Breas Cancer, Renal Cell Carcinoma, Gastric Cancer, Pancreatic Cancer, Urothelial Cancer | I/II | NCT03576131 |
| IGM-8444 | Combination therapy (FOLFIRI, Bevacizumab, Birinapant, Venetoclax) | Solid Tumor, Colorectal Cancer, Gastric Cancer, Non Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Sarcoma, Chondrosarcoma, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia | I | NCT04553692 |